Clinical Trials Logo

Bradycardia clinical trials

View clinical trials related to Bradycardia.

Filter by:

NCT ID: NCT02930980 Completed - Bradyarrhythmia Clinical Trials

Micra Accelerometer Sensor Study 2

MASS2
Start date: October 14, 2016
Phase: N/A
Study type: Interventional

The purpose of the MASS2 is to characterize accelerometer signals of Micra implantable device during different postures and activities and to understand the source of the sensed motion, in order to test feasibility for future enhancements in device functionalities.

NCT ID: NCT02863666 Completed - Bradycardia Clinical Trials

Verification of Prediction Algorithm

VPAC
Start date: August 11, 2016
Phase:
Study type: Observational

Prospective observational clinical study to verify an algorithm used to predict cardiopulmonary events in patients presenting to the emergency department.

NCT ID: NCT02858583 Completed - Bradycardia Clinical Trials

SI + CC Versus 3:1 C:V Ratio During Neonatal CPR

SURV1VE
Start date: October 19, 2017
Phase: N/A
Study type: Interventional

Research question In newborn infants requiring CPR, does CC superimposed by sustained inflation compared to 3:1 compression to ventilation ratio improves return of spontaneous circulation? Overall objective: CC superimposed by sustained inflation will improve short- and long-term outcomes in preterm (>28 weeks or older) and term newborns. Hypothesis to be tested Primary hypothesis: By using CC superimposed by sustained inflation (CC+SI) during CPR the time needed to achieve return of spontaneous circulation (ROSC) compared to the current 3:1 compression to ventilation (C:V) will be reduced in asphyxiated newborns.

NCT ID: NCT02837445 Active, not recruiting - Bradycardia Clinical Trials

Moderato System: A Double-Blind Randomized Trial Ver 1.1

Start date: July 12, 2016
Phase: N/A
Study type: Interventional

The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System. The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a dual chamber pacemaker in order to reduce their blood pressure. The primary objectives of this study are to provide evidence of safety and clinical efficacy of the anti-hypertensive effects of the Moderato System. This will be accomplished by evaluating changes in blood pressure in an active treatment vs. a control patient population for a period of 6 months. The device will be considered to have a clinical effectiveness with regard to its anti-hypertension functions if there is a statistically significant and clinically meaningful reduction in mean 24-hour ambulatory systolic blood pressure in the treatment group compared to the control group.

NCT ID: NCT02764970 Completed - Bradycardia Clinical Trials

Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol

Start date: February 2015
Phase:
Study type: Observational

Out-patients scheduled for coronary computer tomographic angiography (CCTA) were screened regarding their baseline heart rate. If heart rate was > 75, patients were pretreated with 10mg bisoprolol (group 1) or 10mg bisoprolol plus 7.5mg ivabradine (group 2) to reduce heart rate one our before CCTA was performed. Heart rate, additional use of i.v. bradycardic agents, motion artefacts, radiation dose and drug tolerance was monitored.

NCT ID: NCT02758210 Completed - Clinical trials for Bradycardia, Atrial Tachyarrhythmia

Evaluating the Electro Magnetic Interference of Using Tablet and Smart Phone on Leadless Pacemaker (MICRA)

MICRA
Start date: April 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects that electromagnetic field exposure from using a tablet and smart phone have on a leadless pacemaker (MICRA device).

NCT ID: NCT02711748 Recruiting - Bradycardia Clinical Trials

Can Medical Personnel Properly Proceed in the Case of a Patient With Bradycardia?

Start date: February 2016
Phase: N/A
Study type: Interventional

The study aims to assess the regularity of the proceedings in the case of a patient with bradycardia ECG.

NCT ID: NCT02676011 Completed - Bradycardia Clinical Trials

Brad Arrhythmia Induced by Repeated Succinylcholine During Gynecological Laparoscopic Surgery

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Cardiac arrhythmias are a well-recognized complication of anesthesia for laparoscopy. The aim of this study was to evaluate the efficacy of atropine sulfate for prevention of brad arrhythmia induced by repeated succinylcholine during gynecological laparoscopic surgery.

NCT ID: NCT02666794 Completed - Catecholamines Clinical Trials

Plasmatic Catecholamines: Randomized Controlled Trial Comparing Epidural Versus Combined Spinal-epidural

Start date: July 12, 2017
Phase: N/A
Study type: Interventional

Combined spinal-epidural (CSE) for labor analgesia has been associated with fetal bradycardia and uterine hypertonia, possibly due to asymmetric decrease in catecholamine levels, when compared with epidural analgesia (EP).

NCT ID: NCT02641249 Active, not recruiting - Hypoxia Clinical Trials

Non-invasive Intervention for Apnea of Prematurity

Start date: October 2014
Phase: N/A
Study type: Interventional

Purpose of Study: Apnea of Prematurity (AOP) is common, affecting the majority of infants born <34 weeks gestational age (GA). Apnea is accompanied by intermittent hypoxia (IH), which contributes to multiple pathologies, including retinopathy of prematurity (ROP), sympathetic ganglia injury, impaired pancreatic islet cell and bone development, and neurodevelopmental disabilities. Standard of care for AOP/IH includes prone positioning, positive pressure ventilation, and caffeine therapy, none of which is optimal. The objective is to support breathing in premature infants by using a simple, non-invasive vibratory device placed over limb proprioceptor fibers, an intervention using the principle that limb movements facilitate breathing. Methods Used: Premature infants (23-34 wks GA) with clinical evidence of AOP/IH were enrolled 1 week after birth. Caffeine therapy was not a reason for exclusion. Small vibration devices were placed on one hand and one foot and activated in a 6 hour ON/OFF sequence for a total of 24 hours. Heart rate, respiratory rate, oxygen saturation (SpO2), and breathing pauses were continuously collected.